23 completed, 9 recruiting, 7 terminated, 5 active not recruiting. 49 Phase 1, 12 Phase 2.
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy α-Syn H21 Monoclonal Antibody - Multiple System Atrophy | Phase 1 | Not yet recruiting | Ruijin Hospital | 3 | 2026-09-15 | 2026-08-19 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-09-01 | 2026-10-07 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA SST001 - Multiple System Atrophy (MSA), Parkinson's Disease (PD) | Phase 1 | Recruiting | Synusight Biotech (Shanghai) Co., Ltd. | 30 | 2026-06-15 | 2026-09-01 |
| CE-STAND: Cervical Epidural STimulation After Neurologic Damage Epidural Spinal Cord Stimulation System - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | University of Minnesota | 36 | 2026-03-15 | 2026-03-27 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) ALN-SNCA, Placebo - Parkinsons Disease | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 46 | 2025-12-05 | 2026-09-21 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases hUC-MSC-sEV-001 nasal drops - Alzheimer Disease, Parkinson Disease | Phase 1 | Not yet recruiting | Xuanwu Hospital, Beijing | 120 | 2025-07-01 | 2025-07-08 |
| Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies Sural Nerve Graft to the Substantia Nigra, Sham surgery - Multiple System Atrophy, Parkinsons Disease | Phase 1 | Recruiting | Craig van Horne, MD, PhD | 7 | 2025-02-25 | 2026-08-31 |
| GDNF Gene Therapy for Multiple System Atrophy AAV2-GDNF gene therapy, Sham (Placebo) Surgery - Multiple System Atrophy | Phase 1 | Active not recruiting | Brain Neurotherapy Bio, Inc. | 9 | 2023-10-03 | 2026-01-30 |
| UB-312 in Patients With Synucleinopathies UB-312 Injection, Placebo Injection - Multiple System Atrophy, Parkinson Disease | Phase 1 | Completed | NYU Langone Health | 8 | 2023-05-31 | 2026-03-16 |
| Effect of Stellate Ganglion Block on ME/CFS Bupivacaine Injection - Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome | Phase 1 | Completed | Neuroversion, Inc. | 10 | 2023-03-15 | 2024-12-06 |
| Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID stellate ganglion block with 0.5% bupivacaine - Post Acute COVID-19 Syndrome, Long COVID | Phase 1 | Completed | Jonathann Kuo, MD | 20 | 2023-01-03 | 2025-03-13 |
| Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA) hOMSC300 - Multiple System Atrophy, MSA - Multiple System Atrophy | Phase 1 | Active not recruiting | Cytora Ltd. | 10 | 2022-11-07 | 2025-01-29 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) ION464, Placebo - Multiple System Atrophy | Phase 1 | Recruiting | Ionis Pharmaceuticals, Inc. | 40 | 2022-07-21 | 2026-04-27 |
| Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein [18F]UCB-2897 - Parkinson Disease, Multisystem Atrophy | Phase 1 | Completed | Invicro | 5 | 2022-01-31 | 2025-02-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease anle138b, Placebo - Parkinson Disease | Phase 1 | Completed | MODAG GmbH | 70 | 2020-12-22 | 2023-03-22 |
| [18F]F-DOPA Imaging in Patients With Autonomic Failure [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Recruiting | Daniel Claassen | 40 | 2020-02-04 | 2026-03-16 |
| A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects anle138b, Placebo - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 68 | 2019-12-06 | 2020-08-06 |
Showing 20 of 49. Sign in to see all of them.
Multiple System Atrophy (25) · Parkinson Disease (16) · Hypotension, Orthostatic (12) · Postural Orthostatic Tachycardia Syndrome (9) · Pure Autonomic Failure (9) · Orthostatic Intolerance (8) · Shy-Drager Syndrome (5) · Alzheimer Disease (4) · Autonomic Nervous System Diseases (4) · Hypertension (4) · Neurodegenerative Diseases (4) · Fatigue Syndrome, Chronic (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Tachycardia (3) · Tauopathies (3)
Nervous System Diseases (49) · Autonomic Nervous System Diseases (45) · Central Nervous System Diseases (33) · Brain Diseases (31) · Basal Ganglia Diseases (30) · Movement Disorders (30) · Synucleinopathies (27) · Neurodegenerative Diseases (25) · Cardiovascular Diseases (22) · Vascular Diseases (19) · Hypotension (17) · Parkinsonian Disorders (16) · Orthostatic Intolerance (15) · Pathological Conditions, Signs and Symptoms (13)
Midodrine (5) · Carbidopa (4) · Droxidopa (4) · Saline Solution (4) · Sodium Chloride (4) · 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3) · Atomoxetine Hydrochloride (3) · Clonidine (3) · entacapone (3) · Acetazolamide (2) · Bupivacaine (2) · Captopril (2) · Indomethacin (2) · Losartan (2) · Modafinil (2)
Vanderbilt University (8) · Vanderbilt University Medical Center (7) · MODAG GmbH (3) · NYU Langone Health (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Affiris AG (1) · Beth Israel Deaconess Medical Center (1) · Brain Neurotherapy Bio, Inc. (1) · Corestemchemon, Inc. (1) · Craig van Horne, MD, PhD (1) · Cytora Ltd. (1) · Daniel Claassen (1) · Invicro (1) · Ionis Pharmaceuticals, Inc. (1) · Jonathann Kuo, MD (1)
United States (34) · United Kingdom (4) · China (3) · Australia (2) · France (2) · Israel (2) · Austria (1) · Canada (1) · Germany (1) · Netherlands (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Italo Biaggioni, MD (10) · Horacio Kaufmann, MD (2) · Italo Biaggioni, M.D. (2) · Luis E Okamoto, MD (2) · Nand Singh, BSc, MD, DPM, MFPM (2) · Amie Jones, MD (1) · Amnon Mosek, MD (1) · Amy Knorr, MD (1) · Ann Parr, MD, PhD (1) · Craig van Horne, MD, PhD (1) · Cyndya Shiabao, M.D. (1) · David Russell, MD, Ph.D (1) · David S Goldstein, M.D. (1) · Deborah L Duricka, PhD (1)
PMID 11927799, PMID 12119802, PMID 15738343, PMID 10662747, PMID 10851208, PMID 11904109, PMID 12832331, PMID 12923400, PMID 15066944, PMID 15710782, PMID 15911704, PMID 16391172, PMID 16533484, PMID 17116758, PMID 17515447, PMID 17515448, PMID 18426998, PMID 19047577, PMID 19687359, PMID 19738158, PMID 20837887, PMID 21906029, PMID 22247480, PMID 22311903, PMID 22469621, PMID 22801444, PMID 23266540, PMID 24002370, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 27153166, PMID 27271310, PMID 27778639, PMID 29451447, PMID 30363894, PMID 32673517, PMID 32882100, PMID 34000076, PMID 35500536, PMID 35949912, PMID 39727053, PMID 41688122, PMID 9369256, PMID 9727818, PMID 9890307
2019 (2), R01HL144568 (2), 2014 (1), 2025 (1), R01HL059459 (1), R21NS094644 (1), UL1TR000445 (1), UL1TR001998 (1)